IP Library › Granted Patent US 12,622,907
Granted Patent B2
US 12,622,907 · App. 18/696,459 · Granted May 12, 2026

Hair loss therapy

Inventor: Animesh Sinha (Amherst, NY)
Assignee: NIRMANA HEALTH, INC.
A61K31/506A61K9/0053A61K31/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,907
App. No.
18/696,459
Granted
May 12, 2026
Kind
B2
Abstract

This disclosure relates to a single pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of both minoxidil, or a similar antihypertensive vasodilator, and a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. This disclosure also relates to a pharmaceutical package comprising a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. The disclosure further provides methods of treating or preventing hair loss in a subject using the disclosed compositions and packages.

Claims (24)

1 . A pharmaceutical package for treating or preventing hair loss in a subject comprising a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor.

2 . The pharmaceutical package of claim 1 , wherein the package comprises a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil.

3 . The pharmaceutical package of claim 2 , wherein the 5-alpha reductase inhibitor is finasteride.

4 . The pharmaceutical package of claim 3 , wherein the pharmaceutical package is a blister pack.

5 . The pharmaceutical package of claim 3 , wherein either the pharmaceutical composition comprising minoxidil, or the pharmaceutical composition comprising finasteride is in liquid form.

6 . The pharmaceutical package of claim 3 , wherein both the pharmaceutical composition comprising minoxidil, or the pharmaceutical composition comprising finasteride are in liquid form.

7 . The pharmaceutical package of claim 3 , wherein the composition comprising finasteride comprises 1.5 mg to 5 mg finasteride.

8 . The pharmaceutical package of claim 3 , wherein the composition comprising minoxidil comprises 5 mg to 10 mg minoxidil.

9 . The pharmaceutical package of claim 3 , wherein the composition comprising minoxidil comprises 5 mg minoxidil or 10 mg minoxidil.

10 . A single pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and 1.5 mg to 5 mg finasteride for treating or preventing hair loss in a subject.

11 . The single composition of claim 10 comprising a therapeutically effective or prophylactically effective amount of minoxidil and 1.5 mg to 5 mg finasteride for treating or preventing hair loss in a subject.

12 . The single composition of claim 11 , wherein the composition comprising minoxidil comprises 5 mg to 10 mg minoxidil.

13 . The single composition of claim 11 , wherein the composition comprising minoxidil comprises 5 mg minoxidil or 10 mg minoxidil.

14 . The single composition of claim 11 , wherein the single composition results from mixing two pharmaceutical compositions in liquid form, a first pharmaceutical composition and a second pharmaceutical composition, together shortly before being administered to the subject, wherein the two compositions are contained in a pharmaceutical package for treating or preventing hair loss in the subject, said package comprising the first pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, and the second pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of 1.5 mg to 5 mg finasteride; wherein the pharmaceutical package is a blister pack.

15 . The single composition of claim 11 , wherein the pharmaceutical package is a blister pack.

16 . A method of treating or preventing hair loss in a subject in need thereof comprising administering by oral administration a single pharmaceutical composition of claim 11 to said subject.

17 . The method of claim 16 , wherein the subject is male.

18 . A method of treating or preventing hair loss in a subject in need thereof comprising administering to said subject by oral administration a first pharmaceutical composition of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a second pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor, wherein the first pharmaceutical composition and the second pharmaceutical composition are contained in a pharmaceutical package of claim 2 .

19 . The method of claim 18 , wherein the first pharmaceutical composition comprises a therapeutically effective or prophylactically effective amount of minoxidil.

20 . The method of claim 18 , wherein the 5-alpha reductase inhibitor is finasteride.

21 . The method of claim 18 , wherein the subject is male.

22 . The method of claim 18 , further comprising administering to the subject by topical administration a first topical pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and/or a second topical pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor.

23 . The method of claims 22 , wherein the 5-alpha reductase inhibitor is finasteride.

24 . The method of claim 22 , wherein the first topical pharmaceutical composition comprises a therapeutically effective or prophylactically effective amount of minoxidil.

Assignments (1)
CHANGE OF NAME Recorded Apr 18, 2024
From: NIRMANA BIO, INC.
To: NIRMANA HEALTH, INC.
Reel/Frame 067144/0653 →
Continuity (2)
Provisional Application 63250009 · Sep 29, 2021
Related Publication 20240374594A1 · Nov 14, 2024
References Cited (10)
US 20140113887A1 · Park · 2014 [cited by applicant]
US 20210283038A1 · Sekavat · 2021 [cited by applicant]
AU 2011100917A4 · 2011 [cited by applicant]
IT UB20160806A1 · 2017 [cited by applicant]
KR 20220132802A · 2022 [cited by applicant]
WO 2016065426A1 · 2016 [cited by applicant]
WO WO2016065426 · 2016 [cited by examiner]
International Application No. PCT/US2025/053095, International Search Report and Written Opinion mailed Feb. 27, 2026, 17 pages. [cited by applicant]
Chandrashekar BS et al., “Topical Minoxidil Fortified with Finasteride: An Account of Maintenance of Hair Density After Replacing Oral Finasteride,” Indian Dermatology Online Journal, vol. 6, No. 1, Jan. 1, 2015. [cited by applicant]
International Search Report and Written Opinion received in PCT/US2022/044912 dated Jan. 12, 2023, pp. 9. [cited by applicant]